The expression and clinical significance of PRMT5 and CDKN2B in cervical cancer tissue

Hu Xiaohan; Zhou Qiang; Sun Wu; Chen Jing; Shen Han; Li Qiang

doi:10.3969/j.issn.1671-6450.2024.04.006

Abstract：Objective To investigate the expression and clinical significance of protein arginine methyltransferase 5(PRMT5)and cyclin dependent kinase inhibitor 2B(CDKN2B)in cervical cancer.Methods The clinical data of 88 cervical cancer patients who treated in the Department of Obstetrics and Gynecology,Gulou Hospital Affiliated to Nanjing Universi-ty School of Medicine from March 2019 to March 2020 were collected.Immunohistochemical method was used to detect the expression of PRMT5 and CDKN2B in cervical cancer and adjacent tissues.The correlation between PRMT5 and CDKN2B expression was analyzed using Spearman correlation analysis.The differences of PRMT5,CDKN2B in cervical cancer tissues with different clinical characteristics were compared.Kaplan-Meier curve was used to evaluate the impact of PRMT5 and CDKN2B expression on the progression free survival prognosis of cervical cancer patients.Multivariate Cox regression anal-ysis was used to analyze factors influencing the progression free survival prognosis of cervical cancer patients.Results The positive rate of PRMT5 protein in cancer tissue was 70.45%(62/88),which was higher than 6.82%(6/88)in adjacent tis-sues(χ2 =75.155,P=＜0.001).The positive rate of CDKN2B in cervical cancer tissue was 22.73%(20/88),lower than 79.55%(71/88)in adjacent tissues(χ2 =75.336,P＜0.001).There was a significant negative correlation between PRMT5 and CDKN2B in cervical cancer(r=-0.734,P＜0.001).The positive rates of PRMT5 and CDKN2B in cervical cancer tissues with different FIGO stages and lymph node metastasis were statistically significant(P＜0.05).The cumulative 3-year progres-sion free survival rates of the PRMT5 positive and negative groups were 74.19%(46/62)and 92.31%(24/26),respectively,the cumulative 3-year progression free survival rate of the PRMT5 positive group was lower than that of the PRMT5 nega-tive group(Log Rank χ2 =4.386,P=0.017).The 3-year progression free survival rates of the CDKN2B negative and positive groups were 75.00%(51/68)and 95.00%(19/20),respectively,the cumulative 3-year progression free survival rate of the CD-KN2B negative group was lower than that of the CDKN2B positive group,and the difference was statistically significant(Log Rank χ2 =4.423,P=0.012).FIGO staging Ⅰ B2 to Ⅱ A,combined with lymph node metastasis,positive PRMT5,and negative CDKN2B were independent risk factors affecting the progression free prognosis of cervical cancer patients[OR(95%CI)=1.407(1.159-1.696),1.464(1.201-1.784),1.614(1.189-2.192),1.595(1.191-2.136)].Conclusion The increased expression of PRMT5 and the decreased expression of CDKN2B in cervical cancer tissue are related to the adverse clinical pathological characteristics of cervical cancer patients,and are biomarkers for evaluating the prognosis of cervical cancer.